ArticleMolecular biotechnology2026
A Comprehensive Integrated Pipeline for Detection and Annotation of Variants in Whole Exome Sequencing Data.
Article in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Whole exome sequencing (WES) focuses on the protein-coding regions of the genome and it serves as a cost-effective technique for identifying disease-causing mutations. However, the analysis of WES data remains time-consuming and complicated due to the extensive amount of data generated and the numerous tools available to analyze the data. In this study, we have developed an integrated pipeline for detecting and annotating genetic variants in WES data. The developed pipeline helps in efficiently analyzing the large volumes of genomic information produced by WES. It streamlines the workflow by integrating several open-source bioinformatics tools within the Snakemake workflow management system (WMS), ensuring scalability, reproducibility, and ease of use. The developed Snakemake pipeline covers the entire WES analysis workflow, from initial quality control and pre-processing of raw sequencing data to final variant calling and annotation. It includes implementing robust quality control measures using tools like FastQC and Trimmomatic and developing efficient read mapping with Burrows-Wheeler Aligner-Maximum Exact Matches (BWA). It also focuses on creating accurate variant calling and filtration processes using GATK (Genome Analysis Toolkit). This work also focuses on building a comprehensive variant annotation approach. This process encompasses a fully integrated, end-to-end pipeline for WES analysis. The pipeline will significantly improve accuracy in identifying clinically relevant genetic variants. It provides a standardized and reproducible workflow for clinical research. Furthermore, its open-source nature will allow for community contributions and ongoing refinement of WES analysis methods, ensuring that the pipeline remains at the forefront of genomic research technologies for disease diagnosis.
Indexed as
Identifiers
42637907What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.